AI Engines For more Details: Perplexity Kagi Labs You
Antihistaminic Effects: Mizolastine exerts its therapeutic effects by blocking the action of histamine at the H1 receptors. Histamine is a chemical released by the body during allergic reactions, causing symptoms such as sneezing, itching, watery eyes, and runny nose. By inhibiting histamine activity, mizolastine helps alleviate these allergic symptoms.
Relief of Allergic Rhinitis: Allergic rhinitis is a common condition characterized by inflammation of the nasal passages due to exposure to allergens such as pollen, dust mites, pet dander, or mold. Mizolastine is effective in relieving symptoms of allergic rhinitis, including nasal congestion, sneezing, itching, and rhinorrhea (runny nose), thereby improving overall quality of life for affected individuals.
Management of Chronic Urticaria: Chronic urticaria is a skin condition characterized by the recurrent appearance of hives (raised, itchy welts) and/or angioedema (swelling beneath the skin). Mizolastine is effective in managing the symptoms of chronic urticaria, providing relief from itching, reducing the frequency and severity of hives, and improving skin appearance and comfort.
Non-Sedating: Mizolastine belongs to the group of non-sedating or second-generation antihistamines, which are less likely to cause sedation or drowsiness compared to first-generation antihistamines. This makes mizolastine a preferred choice for individuals who need to remain alert and functional during the day while receiving treatment for allergies.
Rapid Onset of Action: Mizolastine has a relatively rapid onset of action, with symptom relief often occurring within 1 to 2 hours after oral administration. This allows for prompt relief of allergic symptoms, enabling individuals to resume their daily activities without significant interruption.
Long Duration of Action: Mizolastine provides prolonged symptom relief, with effects lasting for up to 24 hours following a single dose. This allows for once-daily dosing, which enhances convenience and compliance with treatment regimens.
Side Effects: Common side effects of mizolastine may include headache, dizziness, dry mouth, fatigue, and gastrointestinal disturbances such as nausea or abdominal pain. These side effects are generally mild and transient, but some individuals may experience more pronounced reactions requiring medical attention.
Contraindications: Mizolastine is contraindicated in individuals with severe liver impairment or a history of hypersensitivity to the drug or other antihistamines. Caution should be exercised when prescribing mizolastine to elderly patients or those with impaired renal function, and dosage adjustments may be necessary in these populations.
Interactions: Mizolastine may interact with other medications, including central nervous system depressants, antifungal agents, and certain antibiotics, potentially affecting their efficacy or safety. Patients should inform their healthcare providers about all medications, supplements, and herbal products they are taking to avoid potential drug interactions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0 | 0 | |
| Acne | 0.3 | 0.1 | 2 |
| ADHD | 1.4 | 1.4 | |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 1.5 | 0.3 | 4 |
| Allergies | 2.3 | 1.4 | 0.64 |
| Allergy to milk products | 0.5 | 0.7 | -0.4 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 2.1 | 2.2 | -0.05 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.7 | 0.7 | |
| Ankylosing spondylitis | 1.8 | 0.6 | 2 |
| Anorexia Nervosa | 0.9 | 1.5 | -0.67 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 1.7 | 0.6 | 1.83 |
| Atherosclerosis | 1 | 0.7 | 0.43 |
| Atrial fibrillation | 1.7 | 1.9 | -0.12 |
| Autism | 3.1 | 4 | -0.29 |
| Autoimmune Disease | 0.3 | 0.2 | 0.5 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 0.9 | 0.9 | |
| Brain Trauma | 0.3 | 0.3 | 0 |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.3 | 0.3 | 0 |
| Carcinoma | 1.6 | 0.7 | 1.29 |
| Celiac Disease | 1.2 | 0.7 | 0.71 |
| Cerebral Palsy | 0.8 | 0.3 | 1.67 |
| Chronic Fatigue Syndrome | 1.2 | 2.6 | -1.17 |
| Chronic Kidney Disease | 0.8 | 0.7 | 0.14 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 0.6 | 0.33 |
| Chronic Urticaria (Hives) | 0.5 | 1 | -1 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.3 | 1.33 |
| Cognitive Function | 1 | 0.5 | 1 |
| Colorectal Cancer | 3.9 | 1.1 | 2.55 |
| Constipation | 0.5 | 0.5 | |
| Coronary artery disease | 0.6 | 1.3 | -1.17 |
| COVID-19 | 2.5 | 2.8 | -0.12 |
| Crohn's Disease | 3.2 | 2.1 | 0.52 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.8 | 0.6 | 0.33 |
| Denture Wearers Oral Shifts | 0.8 | 0.8 | |
| Depression | 2.9 | 2.7 | 0.07 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.8 | 1.1 | -0.38 |
| Endometriosis | 1 | 1 | |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 1.6 | 1.3 | 0.23 |
| erectile dysfunction | 0.8 | 0.8 | |
| Fibromyalgia | 1.2 | 1.7 | -0.42 |
| Functional constipation / chronic idiopathic constipation | 1.9 | 2 | -0.05 |
| gallstone disease (gsd) | 1.1 | 0.3 | 2.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 0.3 | 3.33 |
| Generalized anxiety disorder | 0.9 | 0.8 | 0.13 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.2 | 3.5 |
| Graves' disease | 0.7 | 0.6 | 0.17 |
| Gulf War Syndrome | 0.5 | 0.5 | 0 |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 1.1 | 0.4 | 1.75 |
| Heart Failure | 1.7 | 0.8 | 1.13 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| hyperglycemia | 0.2 | 0.7 | -2.5 |
| hypertension (High Blood Pressure | 1.7 | 1 | 0.7 |
| Hypothyroidism | 0.3 | 0.3 | |
| Hypoxia | 1.2 | 0.6 | 1 |
| IgA nephropathy (IgAN) | 1.3 | 1 | 0.3 |
| Inflammatory Bowel Disease | 3 | 3.6 | -0.2 |
| Insomnia | 0.8 | 0.9 | -0.13 |
| Intelligence | 0.6 | 0.6 | 0 |
| Intracranial aneurysms | 1 | 1 | |
| Irritable Bowel Syndrome | 1.7 | 1.6 | 0.06 |
| ischemic stroke | 1 | 0.6 | 0.67 |
| Liver Cirrhosis | 2.4 | 1.1 | 1.18 |
| Long COVID | 1.8 | 1.3 | 0.38 |
| Mast Cell Issues / mastitis | 0.6 | 0.6 | |
| ME/CFS with IBS | 0.5 | 0.3 | 0.67 |
| ME/CFS without IBS | 0.5 | 0.9 | -0.8 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 1.9 | 2.3 | -0.21 |
| Mood Disorders | 3 | 2.7 | 0.11 |
| multiple chemical sensitivity [MCS] | 0.5 | 0.5 | |
| Multiple Sclerosis | 2.3 | 3.8 | -0.65 |
| myasthenia gravis | 0.3 | 0.2 | 0.5 |
| neuropathic pain | 0.7 | -0.7 | |
| Neuropathy (all types) | 0.3 | 0.7 | -1.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.7 | 0.9 | 0.89 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 2.8 | 2.5 | 0.12 |
| obsessive-compulsive disorder | 1.8 | 1.5 | 0.2 |
| Osteoarthritis | 0.9 | 0.6 | 0.5 |
| Osteoporosis | 0.5 | 0.6 | -0.2 |
| pancreatic cancer | 0.9 | 0.6 | 0.5 |
| Parkinson's Disease | 1.9 | 3.3 | -0.74 |
| Polycystic ovary syndrome | 3.4 | 0.8 | 3.25 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.9 | -2 |
| Primary sclerosing cholangitis | 1.5 | 1.2 | 0.25 |
| Psoriasis | 0.9 | 2.5 | -1.78 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.9 | 1.8 | 0.06 |
| Rosacea | 0.1 | 0.2 | -1 |
| Schizophrenia | 1.9 | 0.9 | 1.11 |
| Sjögren syndrome | 1.3 | 1.1 | 0.18 |
| Sleep Apnea | 0.3 | 0.3 | 0 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 1.1 | |
| Stress / posttraumatic stress disorder | 1.2 | 0.7 | 0.71 |
| Systemic Lupus Erythematosus | 1.9 | 0.3 | 5.33 |
| Tic Disorder | 0.5 | 0.6 | -0.2 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 2 | 1.6 | 0.25 |
| Type 2 Diabetes | 2.9 | 2.3 | 0.26 |
| Ulcerative colitis | 2.5 | 2.4 | 0.04 |
| Unhealthy Ageing | 1.9 | 1 | 0.9 |
| Vitiligo | 1.5 | 0.6 | 1.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
